In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...